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1. IntroductIon
Drug photosensitivity can be defined as an abnormal cuta-
neous reaction to light (usually ultraviolet radiation (UVR), es-
pecially UVA) occurring in the setting of drug exposure.1,2
One can, in theory, categorize drug photosensitivity by its 
pathomechanisms as immune-mediated (mostly photoallergy) 
or non-immune mediated (phototoxicity). Most immune-me-
diated reactions present as an eczematous eruption whereas 
classical phototoxicity is described as an acute sunburn. Both 
are predominant in sun-exposed skin, although the eczematous 
pattern tends to be more widespread. There are, however, ins-
tances in which both types of reactions are intertwined and can-
not be separated, both in their clinical features and underlying 
pathomechanisms. Furthermore, there are other examples of 
drug-induced photosensitivity, often overlooked and under 
diagnosed. That is the case of drug-induced lupus erythemato-
sus (LE)3 or drug-induced non-melanoma skin cancer (NMSC). 
In the latter case, there has been increasing evidence for the 
role of widely prescribed photoactive drugs in the development 
of actinic keratosis and NMSC.4-7
More than 300 drugs, topical or systemic, can cause 
Revista SPDV 74(2) 2016; Fotossensibilidade por fármacos; Miguel Gouveia, Ana Gameiro, Inês Coutinho, Margarida Gonçalo.
Fotossensibilidade Induzida por Fármacos 
Miguel Gouveia1, Ana Gameiro1, Inês Coutinho2, Margarida Gonçalo3
1Médico interno do Internato Complementar de Dermatovenereologia, Serviço de Dermatologia, Centro Hospitalar e Universitário 
de Coimbra, Coimbra, Portugal/Resident, Dermatology and Venereology, Centro Hospitalar e Universitário de Coimbra, Portugal
2Assistente Hospitalar de Dermatovenereologia, Serviço de Dermatologia, Centro Hospitalar e Universitário de Coimbra, Coimbra, 
Portugal/Consultant of Dermatology, Dermatology Department, Centro Hospitalar e Universitário de Coimbra, Portugal
3Assistente Hospitalar Graduado Sénior de Dermatologia, Serviço de Dermatologia, Centro Hospitalar e Universitário de Coimbra, 
Coimbra, Portugal e Professor Auxiliar da Faculdade de Medicina da Universidade de Coimbra, Coimbra, Portugal/Senior Graduate 
Assistant in Dermatology, Dermatology Department, Centro Hospitalar e Universitário de Coimbra, Portugal and Professor of 
Dermatology, Dermatology Department, Centro Hospitalar Universitário de Coimbra, Portugal
rESuMo – A fotossensibilidade induzida por fármacos traduz uma resposta cutânea anormal à luz em indivíduos expostos a um fár-
maco, os quais, na sua ausência, tolerariam o mesmo grau de fotoexposição. Pode ocorrer como uma reação aguda ou retardada, 
assumindo características clínicas polimórficas que variam desde a queimadura solar exagerada até aspectos de fotoonicólise, pseudo-
-porfíria, pigmentação, eczema agudo e lúpus eritematoso cutâneo. Os autores descrevem os fármacos mais frequentemente envol-
vidos neste tipo de reações e as formas clínicas mais frequentes e discutem o possível contributo destes fármacos na potenciação da 
fotocarcinogénese. O reconhecimento d estes padrões clínicos de fotossensibilidade e dos fármacos responsáveis é fundamental para 
a evicção do fármaco causal e consequente melhoria ou resolução da reação de fotossensibilidade.
PALAVrAS-cHAVE – Dermatite Fotoalérgica; Dermatite Fototóxica; Fotossensibilidade/induzida quimicamente; Pele/efeito de 
medicamentos.
Drug-Induced Photosensitivity 
ABSTRACT – Drug-induced photosensitivity is an abnormal skin reaction to light in individuals exposed to a drug, whom, in the absence 
of the culprit drug, would tolerate the same amount of light exposure. It can present as an acute or delayed clinical picture, with poly-
morphic features ranging from an exaggerate sunburn to acute eczema, photoonycholysis, pseudo-porphyria, pigmentation or cuta-
neous lupus erythematosus. The authors describe the drugs involved in these photosensitivity reactions and their main clinical pictures 
and discuss the possibility that these drugs can enhance photocarcinogenesis. Clinical recognition of these clinical patterns is of outmost 
importance in order to avoid the culprit drug and consequently improve or resolve photosensitivity.  
KEY-WORDS – Dermatitis, Photoallergic; Dermatitis, Phototoxic; Patch Tests; Photosensitivity Disorders/chemically induced; Skin/drug 
effects.
correspondência: Miguel Gouveia
Centro Hospitalar e Universitário de Coimbra - Serviço de Dermatologia
Praceta Mota Pinto - 3000-075 Coimbra, Portugal
E-mail: miguelpgouveia@gmail.com
recebido/Received
11 Janeiro/11 January 2016 
Aceite/Accepted
9 Março/9 March 2016
124
Educação Médica Contínua
photosensitivity and this list continues to grow, as new drugs 
enter the market and patients’ complexity increases. This pa-
radigm is evident in HIV infection, where photosensitivity inhe-
rent to the disease blends with the added risk of photoactive 
drugs (as efavirenz and tenofovir).8
2. BASIc concEPtS In drug PHotoSEnSItIVIty
Most drug photosensitivity reactions occur within the spec-
trum of UVA wavelength, although some can extend to UVB 
or visible light, generally from natural sun exposure. Artificial 
light, as used in UV lamps in aesthetic, therapeutic or occupa-
tional setting may also be involved. For drug-induced photo-
sensitivity, however, the depth of penetration achieved by UVA 
is paramount in the elicitation of the reaction.9
Classically, drug photosensitivity is divided in photoaller-
gy and phototoxicity (Table 1). Photoallergy is an immune-
-mediated reaction involving T-cell-dependent mechanisms 
and can result in photoallergic contact dermatitis or systemic 
photoallergy. In typical photoallergic reactions, the energy 
from the photon converts the drug into an unstable photopro-
duct, able to combine with an endogenous peptide forming a 
hapten or an antigen. Dendritic cells uptake this antigen and 
pair it with HLA molecules, carry it to the skin-draining lymph 
nodes, where, in the presence of cytokines and co-stimulatory 
molecules, they can stimulate and eventually sensitize naïve T 
cells. The resulting drug-specific T-cells will be mostly respon-
sible for the effector response.10
These reactions develop only in a limited number of in-
dividuals and need previous sensitization. After a certain 
threshold, they are not dose-dependent and can develop even 
with low UV exposure. They resemble mostly eczema, with a 
predominant localization on sun-exposed areas but they can 
spread to non-exposed sites (Fig. 1). There can be cross-reac-
tivity with structurally similar drugs. Histology reveals dermal 
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table 1 - Distinction between phototoxicity and photoallergy
PHototoXIcIty PHotoALLErgy
Frequency Moderate to High Low
Latency period / sensitization None Yes
UV doses / photosensitizer High Low
Cross-reactions No Yes
Basic morphology of lesions Sunburn; Monomorphic Eczema, erythema-multiforme-like
Limits Sharp Diffuse
Covered areas Not involved Possibly involved
Resolution Fast May recur; Persistent reactors
Residual hyperpigmentation Yes Usually not
Histology Sunburn cells Eczematous dermatitis
Pathomechanism
DNA damage/cell death
ROS* production
Inflammation
Type IV hypersensitivity
to photoproducts
*ROS – reactive oxygen species
Figure 1 - Photoallergy reaction to St. John’s Wort infusion. Note the 
eczema spreading to non-photoexposed areas.
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and epidermal T-cell infiltration and spongiosis with formation 
of vesicles.11
Phototoxicity, by definition, does not involve specific im-
mune mechanisms and is caused by the presence of an ab-
normal chromophore in exaggerated amounts in the skin. This 
chromophore can be either the drug itself, a drug metabolite 
or an endogenous chromophore induced by the drug. When 
excited by an UV photon, the chromophore’s energy increa-
ses, entering a singlet state (a short-lived excited state) or a 
triplet state (a more stable, biologically active and long-lived 
state). These molecules then react with neighbouring molecu-
les in a photodynamic reaction, leading to disruption of lipi-
dic cell membranes and changes in the aromatic aminoacids 
of pyrimidine bases of DNA and RNA. Free radicals are also 
formed resulting in the damage of cellular organelles and ul-
timately, cytotoxicity. Inflammatory cytokines such as IL-1, IL-6, 
TNF-alpha and other inflammatory mediators such as prosta-
glandins and leukotrienes also contribute to this inflammatory 
response.1,9,12
Typically, these are the most frequent reactions, developing 
in any individual as long as there is enough photosensitizer 
and sun exposure. They can occur on a first contact, with no 
particular aggravation on further contacts. Clinically they re-
semble acute sunburn with well-demarcated erythema exclusi-
vely on sun-exposed areas, resolving with hyperpigmentation. 
There is no cross-reactivity with other drugs and histology 
shows apoptotic keratinocytes (sunburn cells).11
However, even though the mechanisms of photoaller-
gy and phototoxicity are well established there are overlap-
ping mechanisms as well as clinical manifestations. In fact, 
many drugs can induce photoallergic and phototoxic reac-
tions. For example, the phototoxic furocoumarins, contained 
in plant extracts that are used in “folk medicine” or during 
photochemotherapy, can induce photoallergy.13 The same is 
true for promethazine and lomefloxacin, which have a well-
-established phototoxic potential but can also elicit photoal-
lergic reactions.14-16
Less commonly, other mechanisms of photosensitivity can 
be considered, some immune-mediated like drug-induced LE 
while others are more phototoxic in nature, namely pseudo-
porphyria, photoaging and photocarcinogenesis.
3. cLInIcAL FEAturES oF drug PHotoSEnSItI-
VIty
Photosensitivity can result from systemic uptake or topical 
application of drugs. Cutaneous lesions can vary from urtica-
ria through eczema, subacute LE, vitiligo-like depigmentation, 
dyschromia, NMSC to acute sunburn1,17 (Table 2). The timefra-
me between drug introduction and beginning of skin findings 
can range from a few minutes (in vemurafenib-induced pho-
tosensitivity, for example) to years (in NMSC from voricona-
zole). Most photoallergic and phototoxic reactions, however, 
occur 1 to 2 days after introduction of the drug and sun expo-
sure. For pseudoporphyria, drug-induced LE and photoony-
colysis, it may take several days to weeks.
3.1 Systemic Photosensitvity
From a clinical standpoint, it is useful to divide patterns of 
drug-induced photosensitivity in acute, subacute and delayed 
reactions, since, as we have established previously, they can 
overlap in their pathomechanisms.
3.1.1 Acute Reactions
In acute photoallergy from systemic drugs lesions are 
mainly confluent or non-confluent eczematous patches in 
photo-exposed areas but can sometimes resemble erythema 
multiforme.18,19 They usually involve, in a symmetrical distribu-
tion, the face and forehead, V-shaped area of the neck and 
upper chest, dorsum of the hands and forearms. The shaded 
areas of the face (upper eyelids, upper lip, deep furrows), re-
troauricular and submentonian regions are usually spared. In 
more extensive sun exposure, large body folds, like the axillae, 
groins, finger webs and covered areas (clothes, watch string, 
shoes) are also usually spared. This is especially important 
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table 2 - Clinical patterns of photosensitivity
PrEdoMInAnt In PHototoXIcIty PrEdoMInAnt In PHotoALLErgy
Exaggerated “sunburn”
Urticaria in sun-exposed areas
Pseudoporphyria
Photoonycholysis
Acute and subacute eczema
Hyperpigmentation
Hypopigmentation (vitiligo-like)
Cheilitis
Telangiectasia
Purpura Erythema multiforme-like lesions
Pellagra-like Subacute or chronic lupus erythematosus
Actinic keratosis and squamous cell carcinoma Lichenoid reactions
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when distinguishing systemic photoallergy from airborne der-
matitis, in which the shaded areas typically spared in exposure 
to photoactive drugs can be involved in airborne drug expo-
sure, for example in nurses or other care-givers who crash 
tablets.
A slightly different distribution of lesions can occur, for 
example, in car drivers, who only expose the left side of body, 
giving rise to an asymmetrical pattern of sun-exposure. Fur-
thermore, lesions can be found only on the lower lip, because 
of its higher exposure and thinner stratum corneum.20
Most systemic phototoxic reactions occur between 12-24 
hours after sun-exposure and resemble acute sunburn, with 
sharply delimitated erythema that can progress to vesicles and 
bullae and later to desquamation in large epidermal sheets. 
Residual hyperpigmentation is frequent. 
Some phototoxic drugs, however, can induce immediate 
prickling and burning with transient erythema1 (amiodarone, 
for example – Fig. 2). Immediate burning is also seen with 
more than 50% of patients under vemurafenib treatment for 
metastatic melanoma.21 This can be prevented by sun avoi-
dance and sun protection extending to the long UVA.22, 23 
3.1.2 Subacute Reactions
These reactions usually take several days to weeks to de-
velop, and mainly evoke phototoxic mechanisms as in pseu-
doporphyria, photoonycolysis, dyschromia, telangiectasia and 
purpura, whereas annular lesions may suggest drug-induced 
subacute cutaneous LE.
Drug-induced pseudoporphyria is clinically and histo-
logical indistinguishable from classical porphyria cutanea 
tarda, presenting with chronic skin fragility and flaccid bullae 
on non-inflamed, sun-exposed skin, occasionally progressing 
with the formation of millia. It usually develops within weeks 
to months after drug exposure. This pattern was described ini-
tially with nalidixic acid, furosemide and naproxen1 but it has 
been recognized more recently with celecoxib,24,25 ciprofloxa-
cin,26 voriconazole,27,28 torsemide,29 metformin,30 finasteride31 
and imatinib.32-34
Pseudoporphyria occurs in individuals with no inborn error 
in porphyrin metabolism and as such, no elevation in endo-
genous porphyrins is detected, apart from occasional transient 
increase of uroporphyrins with voriconazole.35
Drug-induced cutaneous lupus erythematosus seems to 
be the consequence of the exaggerated expression of the Ro/
SSA antigen on the surface of keratinocytes in the presence 
of the drug, however, the precise mechanisms underlying this 
reaction are not known.36 Annular lesions are clinically and 
on histopathology similar to idiopathic form of subacute cuta-
neous LE and are located in photoexposed areas and also in 
usually UV-shaded areas.37,38
Drug-induced subacute cutaneous LE usually develops 
weeks or months after drug exposure and is associated with a 
long list of drugs,39 namely thiazide diuretics, calcium channel 
blockers, ACE inhibitors,36 but particularly with terbinafine3,39 – 
the drug with the highest odds ratio for this event.39
Photoonycholysis refers to the half-moon distal onycholy-
sis of one or several nails, described usually 2-3 weeks after 
exposure to tetracyclines (doxycycline)40 (Fig. 3), psoralens and 
fluoroquinolones.41 Although there is no definite explanation 
for this peculiar presentation of photosensitivity, most authors 
point out that the nail plate is relatively unprotected from sun-
light (since it displays less melanin) and suffers from augmen-
tation of sun exposure through the nail plate, acting like a lens 
through which concentrated UVR can enhance inflammation 
and result in nail detachment.40-42
Dyschromia can result from residual hyperpigmentation 
following an acute phototoxicity (Fig.4) and from photoaging 
(enhancement of solar lentigines) induced by some drugs (vo-
riconazole, vandetanib43,44). The accumulation of photoactive 
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Figure 2 - Amiodarone-induced erythema. Note the sparing of the 
wrinkles.
Figure 3 - Minocycline-induced photoonycholysis.
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drugs or their metabolites in the dermis may also lead to dys-
chromia, as is the case for amiodarone,45 minocycline46,47 and 
phenotiazines (especially thioridazine).1 A golden-brown or 
slate grey, bluish colour on sun-exposed areas can even per-
sist longer after stopping these drugs. 
Other clinical manifestations of subacute photosensitivity 
include telangiectasia in sun-exposed areas reported for cal-
cium channel blockers,1 petechial purpura with sharp limits 
on the transition to the shaded areas for ciprofloxacin,48 pella-
gra as a consequence of niacin consumption during prolon-
ged therapy with isoniazid and pellagroid reactions reported 
for anti-cancer agents such as 6-mercaptopurine and 5-fluo-
rouracil.49
3.1.3 Delayed Reactions
Chronic exposure to photoactive drugs can lead to accele-
rated photoaging, actinic keratosis and skin cancers. Vorico-
nazole can result in dyschromia, lentigines, actinic keratosis 
and squamous cell carcinomas, even in children,7,50 and there 
is consensual agreement on dose-dependent increased risk for 
skin cancers after long-time PUVA phototherapy.51 Naproxen, 
chlorpromazine and fluoroquinolones, especially lomefloxa-
cin, can augment DNA aggression induced in vitro by UV and 
result in epidermal neoplasia in animals.52 In humans, po-
tentially photosensitizing drugs, such as diuretics and cardio-
vascular drugs, are being associated with a rise in cutaneous 
precancerous lesions.4,6 For vemurafenib there is a known risk 
for developing actinic keratoses, keratoacanthoma-like NMSC 
and even new melanomas but, probably, this is independent 
of photosensitivity and mostly dependent on the activation of 
alternate signalling pathways after BRAF inhibition.21,22
3.2 topical Photossensitivity
Topical photosensitizers are responsible mostly for acute 
reactions. Generally, in phototoxic contact dermatitis lesions 
develop minutes to days after sun-exposure, and in photoal-
lergic there is a delay of usually 24 to 48 hours after ultraviolet 
exposure.53 Immediate urticarial reactions, like photocontact 
urticaria, have also been described with chlorpromazine54 and 
5-aminolevulinic acid used in photodynamic therapy.55
Clinically, photoallergic contact dermatitis presents as an 
eczematous response, whereas phototoxic appears as erythe-
ma, oedema and bullous lesions. In both types of photo-
contact dermatitis, lesions are localized in sun-exposed skin 
where the drug has been applied. Nevertheless, distant lesions 
can be the result of accidental contact (such as kissing lesions 
in the inner thighs or inadvertent spread by hands or contami-
nated objects56,57). Connubial dermatitis has been described 
for ketoprofen and benzydamine.20,58-61 Also, when the drug 
is used topically in the mouth lesions can manifest as lip and 
chin dermatitis.20,62 If the contact photoallergen is significantly 
absorbed through the skin, it can mimic the distribution of sys-
temic photosensitivity.
Next to the topical NSAIDs, UV filters are the main topical 
photosensitizers,15,63 and given their importance, a brief over-
view of photoallergy to sunscreens evolution is noteworthy.
PABA (p-aminobenzoic acid) was initially the main respon-
sible for photoallergy contact dermatitis although nowadays 
has been largely replaced and is only seldom used.64 Oxy-
benzone (benzophenone 3) was introduced in the 1970 and 
1980’s but despite being replaced in many sunscreens cur-
rently, is still one of the leading causes of positive photopatch 
tests.63 The reasons for the high level of positivity to benzophe-
none 3 are possibly the wide presence in cosmetic products 
and the cross-reactivity with other agents containing benzo-
phenone nucleus, such as ketoprofen and fenofibrate.53,65
Cinnamates and salicylates have also been responsible 
for photoallergic reactions although apparently in a lesser de-
gree.66 Octocrylene, as a result of its wider use and in higher 
concentrations, is being responsible for a raising number of 
cases, notably in children and in adults previously photosensi-
tized to ketoprofen.65,67,68
Concerning the newer UV filters, Mexoryl SX (terephthalyli-
dene dicamphor sulfonic acid), Tinosorb S® (bis-ethylhexylo-
xyphenol methoxyphenyl triazine) and Tinosorb M® (methylene 
bis-benzotriazolyl tetramethylbutylphenol) photoallergys are 
rare, but Tinosorb M® is frequently responsible for contact der-
matitis due to decyl glucoside.65,69-71
As new UV absorbers are introduced, the incidence of 
photoallergic contact dermatitis and causative allergens is li-
kely to evolve. 
4. MAIn drugS cAuSIng PHotoSEnSItIVIty
The list of photosensitizers is large and ever-growing and 
comprises drugs that can be used topically or systemically 
(Table 3). Sometimes, a drug can induce photosensitivity by 
both ways, as piroxicam, for example. Other drugs, like ke-
toprofen, frequently induce a photoallergic contact dermatitis 
with topical use but its concentration on the skin from systemic 
exposure is usually insufficient for inducing photosensitization.
Topical drugs NSAIDs, namely ketoprofen, etofenama-
te, benzydamine and phenothiazine derivatives are the main 
agents responsible for photoallergic contact dermatitis15,63,72-74 
and, by far, responsible for most positive patch-tests in sou-
thern Europe15,72-74 as recently shown also in a multicentre eu-
ropean photopatch test study (The Europen Multicentre Study 
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Figure 4 - Residual hyper and hypopigmented lesions in fenofibrate 
phototoxicity.
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Photopatch Test EMCPPTS – 2012).63 Although not considered 
a drug, UV filters are also an important source of photoaller-
gic contact dermatitis as we have discussed previously.
Main systemic photosensitizers include antimicrobials, es-
pecially tetracyclines, fluoroquinolones, sulphonamides and 
antifungals, NSAIDs and cardiovascular drugs.
Antimicrobials, including tetracyclines and quinolo-
nes are among frequent photosensitizers. Doxycycline and 
less frequently minocycline are phototoxic, can induce pho-
toonycholysis (Fig. 3), pseudoporphyria and for the latter there 
is also the risk of dyschromia, already covered in this arti-
cle.1,40,47
Quinolones, especially fluoroquinolones, can induce pho-
totoxic reactions and pseudoporphyria.26 This was evident for 
the first quinolone antibiotic – nalidixic acid,47 but phototoxicity 
can also occur in up to 15% of patients treated with fleroxacin, 
lomefloxacin, sparfloxacin and pefloxacin, and less frequently 
for ciprofloxacin, norfloxacin, ofloxacin and enoxacin1. Admi-
nistering the drug at night, to reduce drug concentrations in 
circulation during midday can diminish its phototoxic potential. 
Photoallergy with lomefloxacin14,16 (Fig. 5) and enoxacin47 as 
well as cross-reactions with other fluorquinolones (ciprofloxa-
cin and flerofloxacin)75,76 have been described. Fluoroquino-
lones can also photosensitize DNA and have photomutagenic 
and photocarcinogenic properties.52
Sulphonamides and sulpha-drugs, like thiazide diu-
retics, sulfonylureas and celecoxib, as well as dapsone 
(diaminodiphenylsulfone), have been reported to cause pho-
tosensitivity.47,77 Apparently, this side effect is not so frequent 
with cotrimoxazole.1,47
Systemic phenothiazines (chlorpromazine and thiorida-
zine) are not only phototoxic but can also induce lichenoid 
lesions with residual hyperpigmentation.1 Promethazine, still 
used as a topical antipruritic, can induce both a phototoxic 
and photoallergic contact dermatitis.15,78 Other topical pheno-
thiazines, like chlorproethazine used as a muscle relaxant and 
isothipendyl chlorhydrate, used as an antipruritic agent caused 
photoallergy and positive patch tests to chlorpromazine.79,80
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table 3 - Main drugs causing photosensitivity
SyStEMIc PHotoSEnSItIVty toPIcAL PHotoSEnSItIVIty
Antimicrobials Antidepressants NSAIDs
Tetracyclinesa (doxycline, minocycline) Clomipramine, imipramine, sertraline
Ketoprofenc
Piroxicamc, etofenamatec
Piroxicamc, etofenamatec benzydamine
Diclofenac
Sulphonamides (sulfamethoxazole) Cardiovascular drugs Phenothiazines
Fluoroquinolones (lomefloxacin, 
ciprofloxacin)a
Amiodaronea, quinidine
Chlorpromazine
Promethazine, chlorhydrate chlorproethazine
Voriconazolea,b 
Furosemide, torasemide and thiazide 
diuretics
Plants (used as drugs)
Terbinafine, griseofulvina Anti-cancer agents Ruta graveola (common rue)
Efavirenz, tenofovir, faldeprevir Paclitaxel, docetaxel Photodynamic therapy agents
NSAIDs Methotrexate, 5-fluoracil 5-aminolevulinic acid
Arylpropionic acids:
Tiaprofenic acida, suprofen
Naproxen, ibuprofen, ibuproxam, 
carprofena
Dacarbazine
Miscellaneous
Psoralensb, Fenofibrate, simvastatin
Piroxicamc,d
Sulfonylureas, sitagliptin, metformin
Flutamide, finasteride, pirfenidone
Celecoxib, diclofenacd
Azapropazone, phenylbutazone, 
indomethacin
Retinoids 
Phenothiazines Plants (used as drugs)a
Chlorpromazined, thioridazine Hypericum perforatum (St. John’s wort)
Targeted therapies
Kava extracts
Vemurafenibb, imatinib, vandetanib
aMainly phototoxic; bAn increase of NMSC and actinic keratosis; cMainly photoallergic
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Amiodarone, as previously discussed, can induce erythe-
ma (Fig. 2) followed by a bluish-grey hyperpigmentation in 
sun-exposed areas.45
Antifungals comprise many agents with photosensitizing 
properties, namely griseofulvin, terbinafine and voriconazo-
le. The first two can be found to aggravate lupus erythemato-
sus, even inducing subacute lupus erythematosus in patients 
who develop anti-Ro/SS-A antibodies.3,39
Photosensitivity to voriconazole is seemingly not extensive 
to other azole antifungals. This drug is used mainly in invasi-
ve aspergillosis or refractory candidiasis, generally in patients 
with previous immunosuppression, either from underlying di-
seases or from therapeutic immunosuppressants, therefore 
in individuals with a considerably risk for photosensitivity50,81 
Photosensitivity from voriconazole can manifest as a sun-
burn reaction with cheilitis and erosions of the lower lip28,50,82 
(Fig.6), as pseudoporhyria,27 but also with photoaging with 
solar lentigines and actinic keratosis progressing into multi-
focal invasive squamous cell carcinoma,5,7,83,84 even with de-
-novo melanoma.85
Antiviral agents, especially those used in the treatment of 
HIV and HCV infection, have been described as photosensiti-
zing. Efavirenz, for example, induced papulosquamous annu-
lar lesions on photoexposed areas, only within a few days to 
weeks after initiation of treatment.86,87 Tenofovir, a newer anti-
-retroviral drug has also been reported as inducing systemic 
photoallergy, with positive photopatch tests.88 This is especially 
important when you consider HIV infection in itself as a pho-
tosensitizing condition and a known risk-factor for a variety of 
photosensitive disorders. 
Nonsteroidal anti-inflammatory drugs (NSAIDs) are a 
frequent cause of photosensitivity. This was initially seen with 
benoxaprofen, calling attention for this adverse event not only 
with this agent but to many others within this class (carprofen, 
naproxen, suprofen, ketoprofen, ibuprofen and tiaprofenic 
acid). Other NSAIDs, namely diclofenac, piroxicam, celeco-
xib, benzydamine and etofenamate were also documented as 
photosensitizers. For tiaprofenic acid, for example, in vitro and 
in vivo phototoxic potencial was reported,89,90 but in other pu-
blications also photoallergic reactions were described,91-93 un-
derlining that both patterns of photosensitivity can be elicited 
by the same agent.
Most topically applied NSAIDs are absorbed through the 
skin and may cause distant lesions resembling a systemic pho-
tosensitivity. Benzydamine, used for oral or genital hygiene, 
causes photosensitivity at distant sites,15 as well as cheilitis and 
chin dermatitis or hand dermatitis caused by the application 
of the drug.15,20
Ketoprofen may cause severe photoallergic reactions, 
with oedema, bullae and even erythema multiforme-like le-
sions.60,81,94-96 These extend well beyond the area of applica-
tion, and can recur on sun-exposure even without further drug 
application,60,94 as the drug or its metabolite can persist in the 
skin for several days.96 Cross-reactions with benzophenone 
and octocrylene in sunscreens60 or benzophenones in magazi-
ne ink97 have also been described. Cross-reactivity also occurs 
between arylpropionic acid derivatives that share the benzo-
phenone structure, namely, tiaprofenic acid and suprofen, but 
is not extensive to naproxen or ibuprofen.
The analogues of ketoprofen, piketoprofen and dexketo-
profen have a similar behaviour concerning photosensitivi-
ty.61,98 New topical formulations of ketoprofen in plaster aim to 
reduce UV exposure of the drug, but do not completely hinder 
this particular side-effect.
Piroxicam is a known photosensitizer since the 1980’s, 
usually reacting on a first exposure because of its close rela-
tion to thiomersal99 and its main sensitizing moiety of the mo-
lecule, thiosalicylic acid.100 Photoallergy can occur both from 
topical and systemic use of the drug but, as this NSAID has 
been replaced by newer drugs, this side effect is becoming less 
Figure 5 - Acute systemic photoallergy reaction induced by lome-
floxacin.
Figure 6 - Voriconazole-induced cheilitis.
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frequent. However, a few cases were still found in the recent 
European multicentre photopatch test study.63 Systemic pho-
tosensitivity develops within 24-48 hours as an acute eczema 
involving the whole face or as scattered erythematous papu-
les and vesicles on the face and dorsum of the hands, often 
pompholyx-type.101-103 Patients displaying this photoallergy do 
not react against tenoxicam, meloxicam or lornoxicam neither 
on photopatch nor on drug rechallenge, as these oxicams do 
not share the thiosalicylate moiety.104 On the contrary, cross-
-reaction between piroxicam and other oxicams occurs regu-
larly in fixed drug eruption.105
More recently, the new kinase inhibitors and new anti-
-cancer drugs deserve a place among the drugs capable of 
eliciting photosensitivity. Vandetanib,106 imatinib and in par-
ticular vemurafenib are known to cause phototoxic reactions. 
Regarding the latter, more than 50% of patients develop bur-
ning and oedematous erythema on sun-exposure22,23 and also 
actinic keratosis and squamous cell carcinoma, as early as 
within 8 weeks of starting therapy.21
Finally, “folk” medicines, mostly based on plant extracts, 
some of them rich in furocoumarins, can obviously result in 
systemic or topical photosensitivity, such as home-made in-
fusions of St. John’s wort (Hypericum perforatum L.)107 (Fig. 1) 
and topically applied infusions of Ruta graveolens.108
5. dIAgnoStIc ProcEdurES In drug PHoto-
SEnSItIVIty
A photosensitive eruption demands a careful and syste-
matic review of all the drugs taken by the patient. Photopatch 
tests are indicated mainly for photoallergic contact dermati-
tis but can also be used to assess systemic drug photoaller-
gy.17,109,110 The recommended European baseline photopatch 
test series includes ketoprofen, etofenamate, piroxicam and 
benzydamine, with the extended series covering also pike-
toprofen, dexketoprofen, ibuprofen, diclofenac, fenofibrate 
and chlorpromazine,111 but any suspected drug can be tested 
according to the general standardized procedures of photo-
patch testing. 
Briefly, allergens are applied in duplicate on the back, 
followed by irradiation of only one of the sets at day 1 or day 
2 with 5 J/cm2 of UVA, whereas the other set is shielded from 
the light. Readings should be performed immediately after ir-
radiation and also 48 and/or 72 h afterwards.112
Photopatch tests results have to be carefully interpreted: 
positive reactions in both sets mean contact allergy that can be 
photoaggravated if the reaction is 1+ more on the irradiated 
side. A photopatch test is positive when erythema and papules 
covering the whole test area is observed only in the irradiated 
set112 (Fig. 7). If the reaction is mainly erythema and oedema, 
without pruritus and exclusively limited to the test chamber 
area, beginning shortly after irradiation, reaching its highest 
intensity by 24h and regressing in 48 to 72h, then it is proba-
bly a phototoxic event. If there is pruritic exanthema with ve-
sicles, diffuse limits extending beyond the chamber area, with 
increasing intensity until 48-72h after irradiation, this is more 
suggestive of a photoallergic reaction.113
In systemic photosensitivity, oral photoprovocation with 
skin irradiation after drug exposure or with the calculation of 
the minimal erythema dose (MED) when exposed to the drug 
and after drug withdrawal may help to identify the culprit.
In phototoxic reactions, both photopatch and photopro-
vocation tests are positive in the majority of tested patients. 
Therefore they are not particularly useful for confirming the 
aetiology of a phototoxic reaction but can disclose a hidden 
photoallergy.
6. gEnErAL PrIncIPLES oF trEAtMEnt oF drug 
PHotoSEnSItIVIty
Drug suspension and sun avoidance are recommended to 
resolve drug photosensitivity. If the drug is essential and life-
-saving, when there is no alternative drug or if the alternative 
drug is inadequate, sun avoidance, physical protection and a 
broad-spectrum sunscreen that covers the spectrum of UVA 
may be adequate to improve photosensitivity. For phototoxic 
reactions, this protective effect of sunscreen is particularly use-
ful, as shown for voriconazole, vemurafenib and amiodarone. 
Figure 7 - Positive photopatch test to benzydamine. Note that the erythema is only seen in the irradiated site.
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Moreover, broad-spectrum sunscreen can be implemented 
as a preventive measure when initiating a known photosensi-
tizer, however one must acknowledge that chemical UV filters 
represent an important cause of contact photosensitivity, parti-
cularly in patients with previous dermatoses.
In cases of acute photoallergy, suspension of the culprit 
drug and sun avoidance won’t resolve the skin lesions within 
a short time and active treatment may be necessary. Topical 
corticosteroids may be prescribed for a few days and severe 
reactions may need an additional short course of oral corti-
costeroids with fast dose tapering. 
Acute phototoxicity, presenting mainly as acute sunburn, 
may benefit greatly from emollients and photoprotection even 
for some time after the reaction, and the efficacy of corticoste-
roids is highly questioned in this setting. 
7. concLuSIon
Phototoxic, photoallergic and overlapping photosensitive 
reactions are still a frequent problem. They can exhibit clinical 
polymorphism, different time courses and late consequences. 
Culprit drugs often depend on geographic areas and pres-
cription habits, changing also over time. 
The dermatologist must be alert not only for the multiple 
clinical patterns that can result from photosensitivity but also 
for the many drugs that can cause it. A thorough review of 
all systemic and topical agents, including “folk” medicine, 
should be conducted and complementary tests such as photo-
patch tests, phototests and photoprovocation may contribute 
to a final etiologic diagnosis. These proceedings may finally 
allow adequate patient advice concerning further eviction of 
the photosensitizer and related chemicals and greatly improve 
the patient’s quality of life.
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1.  Which of the following features is not charac-
teristic of a photoallergic reaction?
a) Immune-mediated reaction involving T-cell depen-
dent mechanism
b) Resolves with hyperpigmentation
c) Onset even with low UV exposure
d) Clinically resembles eczema that is predominant 
on sun-exposed areas but can spread to non-ex-
posed sites
 
2. Which of the following features is not charac-
teristic of a phototoxic reaction?
a)  More frequent than photoallergy
b) Can develop on any individual as long as there is 
enough photosensitizer and sun exposure 
c)  Cross reactions with other drugs may occur
d) Clinically resembles acute sunburn
3. Which drug is most likely to induce subacute 
cutaneous lupus erythematosus?
a)  Terbinafine
b) Hydroclorothiazide
c)  Amlodipine
d) Perindopril
4. considering photocarcinogenesis, select the 
the wrong sentence
a)  Voriconazole can result in squamous cell carcino-
ma even in children
b) PUVA is not associated with increased risk for skin 
cancer
c)  Vemurafenib can result in de novo melanomas
d) Diuretics are being associated with a rise in cuta-
neous precancerous lesions 
5. nSAIds are important photosensitizers. Select 
the correct sentence
a)  Systemic ketoprofen commonly induces photosen-
sitization
b) The new topical formulation of ketoprofen in plas-
ter is effective in preventing photosensitization
c)  Piroxicam-induced photoallergy can occur from 
both topical or systemic use
d) Piroxicam cross-reacts with tenoxicam, meloxicam 
or lornoxicam
6. Minocycline can be responsible for which reac-
tions?
a)  Photoonycholysis
b) Pseudoporhyria
c)  Dyschromia
d) All of the above
 
7. considering photopatch tests, select the wrong 
sentence
a)  Allergens are applied in duplicate on the back, 
followed by irradiation of only one of the sets at 
day 1 or day 2 with 5 J/cm2 of UVA, whereas the 
other set is shielded from the light.
b) Positive reaction in both irradiated and non-irra-
diated set of allergens means contact allergy
c)  A photopatch test is positive when erythema and 
papules covering the whole test area is observed 
only in the irradiated region
d) Early reaction, with erythema, oedema and pru-
ritus reaching its highest intensity by 24h and 
regressing in 48 to 72 h suggests photoallergy
ASSESS WHAT YOU HAVE LEARNED
Key: 1-b), 2-c), 3-a), 4-b), 5-c), 6-d), 7-d)
